SlideShare a Scribd company logo
Vulnerable Plaque SymposiumVulnerable Plaque Symposium
Patients with High CRP & HighPatients with High CRP & High
CT Calcium Score are at Higher Risk:CT Calcium Score are at Higher Risk:
How Can Calcium ScoreHow Can Calcium Score
Improve Your Practice?Improve Your Practice?
John A. Rumberger, PhD, MD, FACCJohn A. Rumberger, PhD, MD, FACC
Clinical Professor of Medicine, Ohio State UniversityClinical Professor of Medicine, Ohio State University
Medical DirectorMedical Director
Physician’s Prevention and Wellness CenterPhysician’s Prevention and Wellness Center
Columbus, OhioColumbus, Ohio
Chicago, ILChicago, IL
March 29, 2003March 29, 2003© 2003 John A Rumberger, MD
1.25
1.6
1.6
1.8
2.15
2.35
2.5
5
0 2 4 6 8 10
Lp(a)
Homocysteine
TC
Fibr
t-PA Ag
TC/HDL
hs-CRP
hs-CRP + TC/HDL
RR in men from the
Physicians Health Study
Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People
Values in the Highest Quartile Compared to Lowest Quartile
hs C-Reactive Proteinhs C-Reactive Protein
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD
o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction”
o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis”
o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By
Elevated BP ETOH consumptionElevated BP ETOH consumption
BMI Aerobic exerciseBMI Aerobic exercise
Metabolic syndrome Weight lossMetabolic syndrome Weight loss
Hormone use Medications:Hormone use Medications:
Chronic infections statins, fibrates,Chronic infections statins, fibrates,
Chronic inflammation niacinChronic inflammation niacin
hs C-Reactive Proteinhs C-Reactive Protein
o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease
o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern”
o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis”
rather than its extentrather than its extent
VTVT
VT = “vulnerable threshold”VT = “vulnerable threshold”
““vulnerability”vulnerability”
TimeTime
Patient APatient A
Patient BPatient B
MI/SCDMI/SCD
The “Vulnerable Threshold”
CRPCRP
CRPCRP
CRPCRP
©
© 2003 John A Rumberger, MD
©
CT Coronary Artery CalciumCT Coronary Artery Calcium
No CalcificationNo Calcification Severe CalcificationSevere Calcification
Left Main
LAD
LCX
AoAo
LALA
PAPA
Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and
Coronary Artery Plaque AreaCoronary Artery Plaque Area
0
2
4
6
8
10
12
14
16
0 2 4 6 8
Square Root Sum of Calcium Areas
SquareRootSumof
PlaqueAreas
Rumberger, Circ 1995:92:2157-62
n = 38n = 38
r = 0.90r = 0.90
p < .001p < .001
No. of coronary segments/pt. with plaques (IVUS)No. of coronary segments/pt. with plaques (IVUS)
0 1 2 3 4 5 6 7
No. of calcifiedNo. of calcified
coronarycoronary
segments/pt.segments/pt.
(EBCT)(EBCT)
0
1
2
3
4
5
6
7
Y = -0.67 + (0.90 * X)
r = 0.86
p < 0.0001 N = 40 patients
total of 222 coronary
segments examined
# of segments with EBT calcium vs. # of segments with any plaque# of segments with EBT calcium vs. # of segments with any plaque
Schmermund et alSchmermund et al
AJC 1998; 81:AJC 1998; 81:
141-146141-146
EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium
 Define the extent of ASO disease?Define the extent of ASO disease?
YESYES
 The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto
the amount of measurable coronary disease by:the amount of measurable coronary disease by:
1) direct histopathologic comparison1) direct histopathologic comparison
2) with intravascular ultrasound2) with intravascular ultrasound
3
4.4
8.8
0
2
4
6
8
10
Score 0 Score 1-15 Score 16-
80
Score 81-
270
Score
>271
Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT:
926 initially asymptomatic patients926 initially asymptomatic patients
1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile
* AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes
Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498
RelativeRisk(RR)RelativeRisk(RR)
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199
0.36 0.51 0.71
0.99
1.38
1.92
2.64
3.62
4.9
6.54
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
676 initially asymptomatic patients676 initially asymptomatic patients
3232++7 months f/u7 months f/u
AnnualAnnual AbsoluteAbsolute RiskRisk
EBT CVSEBT CVS (volume score)(volume score) Progression and MIProgression and MI
Raggi, Shaw, Callister, Budoff; JACC 2003Raggi, Shaw, Callister, Budoff; JACC 2003 (retrospective analysis)(retrospective analysis)
0
10
20
30
40
50
60
No MI MI
MeanChangeinCVS/yearMeanChangeinCVS/year
26+1.5%
47.5+7.5% *
n = 833, 2.1+1.4 yr f/u,
45 documented MI (2.2%/yr)
Stepwise Cox Model
Independent Predictors of MI
 Elevated cholesterol
 Diabetes
 Initial EBT-CVS
 % Change in EBT-CVS
Initially asymptomatic patients with CVS > 30 and repeat EBT Scans
Coronary Artery CalcificationCoronary Artery Calcification
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Coronary calcium IS AtherosclerosisCoronary calcium IS Atherosclerosis
o The magnitude of the calcium score relates to the severity of ASO diseaseThe magnitude of the calcium score relates to the severity of ASO disease
o The calcium score as well as the percentile rank provide informationThe calcium score as well as the percentile rank provide information
in which to view risk factors, rather than the other way aroundin which to view risk factors, rather than the other way around
o The data on examining progression of CAD with CT are consistent withThe data on examining progression of CAD with CT are consistent with
the potential for the calcium score/rank to be used as the “goal” of therapythe potential for the calcium score/rank to be used as the “goal” of therapy
RR of non-fatal MI/Cardiac Death:
EBT Score and hs-CRP
6.3 4.3
1.74.9
1.8 1
0
2
4
6
8
High CAC Med. CAC Low CAC
Lowest quartile
hs-CRP
Highest quartile
hs-CRP
Park et al.
Circ. 2002;106-2073-2077
6.3
RelativeRiskRelativeRisk
6.4 yr. f/u, n = 967
initially asymptomatic,
non-diabetic individuals
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
CRP
CRP
Clinical Questions in PreventionClinical Questions in Prevention
In the asymptomatic individual
How aggressive should I be?
 Primary versus secondary prev. goals
How closely should I follow up?
 Routine versus close & repeat testing
hs-CRP CAC Range Level of Aggression, f/u
< 1 mg/L
> 1-3 mg/L
> 3 mg/L
hs-CRP & CAC Scoringhs-CRP & CAC Scoring
Value Range Percentile Range Aggression Clinical f/u
Low
Low
Low
Mod.
Mod.
Mod.
High
High
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
Primary Routine
Primary Routine
Secondary Close
Primary Routine
Primary Close
Secondary Close
Primary Close
Secondary Close
Secondary Close
hs-CRP & CAC Scoringhs-CRP & CAC Scoring
In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals
CAC Scanning with CTCAC Scanning with CT
&&
hs-CRP testinghs-CRP testing
areare ComplementaryComplementary to each otherto each other
and the combination of bothand the combination of both
can be used to refinecan be used to refine
Clinical-Decision making in such patientsClinical-Decision making in such patients

More Related Content

PPT
136 framingham model and coronary events
PPT
CABG is superior to DES (Stent) in MVD - Journal Review
PDF
DR. MAICOL AUGUSTO CORTEZ SANDOVAL/Fibrilacion auricular subclinica
PDF
Lipid lowering therapy in CKD
PPT
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
136 framingham model and coronary events
CABG is superior to DES (Stent) in MVD - Journal Review
DR. MAICOL AUGUSTO CORTEZ SANDOVAL/Fibrilacion auricular subclinica
Lipid lowering therapy in CKD
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...

What's hot (16)

PPT
Cancer related anemia
DOCX
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
PPT
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
PPTX
Novel biomarkers in ovarian carcinoma
PPT
Crizo
PPTX
June 2016 ASCO in Review #CRCWebinar
PPTX
SIDE EFFECTS OF TKIs
PDF
Familial predisposition for colorectal cancers: Who to screen?
PPTX
Astellas meeting, crpc- what we have in 2019
PPTX
Crpc the paradigm of sequence
PDF
Improve it slides
PDF
Anticoagulación en Mieloma Múltiple
PPTX
BEYOND BELATACEPT
PPT
Aeha2004 crp lppla2newtemplate-koenig
Cancer related anemia
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Novel biomarkers in ovarian carcinoma
Crizo
June 2016 ASCO in Review #CRCWebinar
SIDE EFFECTS OF TKIs
Familial predisposition for colorectal cancers: Who to screen?
Astellas meeting, crpc- what we have in 2019
Crpc the paradigm of sequence
Improve it slides
Anticoagulación en Mieloma Múltiple
BEYOND BELATACEPT
Aeha2004 crp lppla2newtemplate-koenig
Ad

Similar to 214 how can calcium score improve your practice (20)

PPT
Ct calcium scoring 1
PPT
CT Calcium Scoring Lecture Overview Powerpoint
PDF
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
PPT
136 framingham model and coronary events
PPT
Vp meeting orlando2003_new template
PPT
Fuster aha-2005-dallas-biomarkers,
PPT
251 computed tomographic coronary artery calcium
PPT
251 computed tomographic coronary artery calcium
PPT
250 patients with very abnormal test results
PPT
Mi or scd in patients with very abnormal cardiac test results
PPT
250 patients with very abnormal test results
PPT
3rd vulnerable plaque rumberger 3 16-02 3
PPS
3rd vulnerable plaque rumberger 3 16-02 3
PPT
3rd vulnerable plaque rumberger 3 16-02 3
PPT
Ebt rumberger- ohio state u- part 3
PPTX
RIESGO CARDIOMETABOLICO
Ct calcium scoring 1
CT Calcium Scoring Lecture Overview Powerpoint
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
136 framingham model and coronary events
Vp meeting orlando2003_new template
Fuster aha-2005-dallas-biomarkers,
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
250 patients with very abnormal test results
Mi or scd in patients with very abnormal cardiac test results
250 patients with very abnormal test results
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3
3rd vulnerable plaque rumberger 3 16-02 3
Ebt rumberger- ohio state u- part 3
RIESGO CARDIOMETABOLICO
Ad

More from Society for Heart Attack Prevention and Eradication (20)

PPTX
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
PPTX
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
PPTX
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
PPTX
AHA SHAPE Symposium 2017 Dr. Yen Presentation
PDF
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
PPT
Vulnerable plaque vulnerable patient
PPT
Vulnerable patient talk in poland
PPT
Vulnerable patient slides without movies
PPT
PPT
Vp watch editorial_slide 25short-
PPT
Vp watch editorial_slide25short-
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
Vulnerable plaque vulnerable patient
Vulnerable patient talk in poland
Vulnerable patient slides without movies
Vp watch editorial_slide 25short-
Vp watch editorial_slide25short-

Recently uploaded (20)

PPTX
Neuropathic pain.ppt treatment managment
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PPTX
CME 2 Acute Chest Pain preentation for education
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
Respiratory drugs, drugs acting on the respi system
PPT
Management of Acute Kidney Injury at LAUTECH
PPTX
surgery guide for USMLE step 2-part 1.pptx
PPT
OPIOID ANALGESICS AND THEIR IMPLICATIONS
PPTX
Note on Abortion.pptx for the student note
PDF
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
DOCX
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
PPTX
Uterus anatomy embryology, and clinical aspects
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
DOC
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
PPTX
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx
Neuropathic pain.ppt treatment managment
Imaging of parasitic D. Case Discussions.pptx
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
CME 2 Acute Chest Pain preentation for education
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Respiratory drugs, drugs acting on the respi system
Management of Acute Kidney Injury at LAUTECH
surgery guide for USMLE step 2-part 1.pptx
OPIOID ANALGESICS AND THEIR IMPLICATIONS
Note on Abortion.pptx for the student note
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
Uterus anatomy embryology, and clinical aspects
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
Adobe Premiere Pro CC Crack With Serial Key Full Free Download 2025
Pathophysiology And Clinical Features Of Peripheral Nervous System .pptx

214 how can calcium score improve your practice

  • 1. Vulnerable Plaque SymposiumVulnerable Plaque Symposium Patients with High CRP & HighPatients with High CRP & High CT Calcium Score are at Higher Risk:CT Calcium Score are at Higher Risk: How Can Calcium ScoreHow Can Calcium Score Improve Your Practice?Improve Your Practice? John A. Rumberger, PhD, MD, FACCJohn A. Rumberger, PhD, MD, FACC Clinical Professor of Medicine, Ohio State UniversityClinical Professor of Medicine, Ohio State University Medical DirectorMedical Director Physician’s Prevention and Wellness CenterPhysician’s Prevention and Wellness Center Columbus, OhioColumbus, Ohio Chicago, ILChicago, IL March 29, 2003March 29, 2003© 2003 John A Rumberger, MD
  • 2. 1.25 1.6 1.6 1.8 2.15 2.35 2.5 5 0 2 4 6 8 10 Lp(a) Homocysteine TC Fibr t-PA Ag TC/HDL hs-CRP hs-CRP + TC/HDL RR in men from the Physicians Health Study Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People Values in the Highest Quartile Compared to Lowest Quartile
  • 3. hs C-Reactive Proteinhs C-Reactive Protein AtAt PRESENTPRESENT the following has been established:the following has been established: o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction” o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis” o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By Elevated BP ETOH consumptionElevated BP ETOH consumption BMI Aerobic exerciseBMI Aerobic exercise Metabolic syndrome Weight lossMetabolic syndrome Weight loss Hormone use Medications:Hormone use Medications: Chronic infections statins, fibrates,Chronic infections statins, fibrates, Chronic inflammation niacinChronic inflammation niacin
  • 4. hs C-Reactive Proteinhs C-Reactive Protein o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern” o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis” rather than its extentrather than its extent
  • 5. VTVT VT = “vulnerable threshold”VT = “vulnerable threshold” ““vulnerability”vulnerability” TimeTime Patient APatient A Patient BPatient B MI/SCDMI/SCD The “Vulnerable Threshold” CRPCRP CRPCRP CRPCRP © © 2003 John A Rumberger, MD ©
  • 6. CT Coronary Artery CalciumCT Coronary Artery Calcium No CalcificationNo Calcification Severe CalcificationSevere Calcification Left Main LAD LCX AoAo LALA PAPA
  • 7. Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and Coronary Artery Plaque AreaCoronary Artery Plaque Area 0 2 4 6 8 10 12 14 16 0 2 4 6 8 Square Root Sum of Calcium Areas SquareRootSumof PlaqueAreas Rumberger, Circ 1995:92:2157-62 n = 38n = 38 r = 0.90r = 0.90 p < .001p < .001
  • 8. No. of coronary segments/pt. with plaques (IVUS)No. of coronary segments/pt. with plaques (IVUS) 0 1 2 3 4 5 6 7 No. of calcifiedNo. of calcified coronarycoronary segments/pt.segments/pt. (EBCT)(EBCT) 0 1 2 3 4 5 6 7 Y = -0.67 + (0.90 * X) r = 0.86 p < 0.0001 N = 40 patients total of 222 coronary segments examined # of segments with EBT calcium vs. # of segments with any plaque# of segments with EBT calcium vs. # of segments with any plaque Schmermund et alSchmermund et al AJC 1998; 81:AJC 1998; 81: 141-146141-146
  • 9. EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium  Define the extent of ASO disease?Define the extent of ASO disease? YESYES  The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto the amount of measurable coronary disease by:the amount of measurable coronary disease by: 1) direct histopathologic comparison1) direct histopathologic comparison 2) with intravascular ultrasound2) with intravascular ultrasound
  • 10. 3 4.4 8.8 0 2 4 6 8 10 Score 0 Score 1-15 Score 16- 80 Score 81- 270 Score >271 Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT: 926 initially asymptomatic patients926 initially asymptomatic patients 1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile * AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498 RelativeRisk(RR)RelativeRisk(RR)
  • 11. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199 0.36 0.51 0.71 0.99 1.38 1.92 2.64 3.62 4.9 6.54 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score 676 initially asymptomatic patients676 initially asymptomatic patients 3232++7 months f/u7 months f/u AnnualAnnual AbsoluteAbsolute RiskRisk
  • 12. EBT CVSEBT CVS (volume score)(volume score) Progression and MIProgression and MI Raggi, Shaw, Callister, Budoff; JACC 2003Raggi, Shaw, Callister, Budoff; JACC 2003 (retrospective analysis)(retrospective analysis) 0 10 20 30 40 50 60 No MI MI MeanChangeinCVS/yearMeanChangeinCVS/year 26+1.5% 47.5+7.5% * n = 833, 2.1+1.4 yr f/u, 45 documented MI (2.2%/yr) Stepwise Cox Model Independent Predictors of MI  Elevated cholesterol  Diabetes  Initial EBT-CVS  % Change in EBT-CVS Initially asymptomatic patients with CVS > 30 and repeat EBT Scans
  • 13. Coronary Artery CalcificationCoronary Artery Calcification AtAt PRESENTPRESENT the following has been established:the following has been established: o Coronary calcium IS AtherosclerosisCoronary calcium IS Atherosclerosis o The magnitude of the calcium score relates to the severity of ASO diseaseThe magnitude of the calcium score relates to the severity of ASO disease o The calcium score as well as the percentile rank provide informationThe calcium score as well as the percentile rank provide information in which to view risk factors, rather than the other way aroundin which to view risk factors, rather than the other way around o The data on examining progression of CAD with CT are consistent withThe data on examining progression of CAD with CT are consistent with the potential for the calcium score/rank to be used as the “goal” of therapythe potential for the calcium score/rank to be used as the “goal” of therapy
  • 14. RR of non-fatal MI/Cardiac Death: EBT Score and hs-CRP 6.3 4.3 1.74.9 1.8 1 0 2 4 6 8 High CAC Med. CAC Low CAC Lowest quartile hs-CRP Highest quartile hs-CRP Park et al. Circ. 2002;106-2073-2077 6.3 RelativeRiskRelativeRisk 6.4 yr. f/u, n = 967 initially asymptomatic, non-diabetic individuals
  • 15. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk
  • 16. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk CRP CRP
  • 17. Clinical Questions in PreventionClinical Questions in Prevention In the asymptomatic individual How aggressive should I be?  Primary versus secondary prev. goals How closely should I follow up?  Routine versus close & repeat testing
  • 18. hs-CRP CAC Range Level of Aggression, f/u < 1 mg/L > 1-3 mg/L > 3 mg/L hs-CRP & CAC Scoringhs-CRP & CAC Scoring Value Range Percentile Range Aggression Clinical f/u Low Low Low Mod. Mod. Mod. High High High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High Primary Routine Primary Routine Secondary Close Primary Routine Primary Close Secondary Close Primary Close Secondary Close Secondary Close
  • 19. hs-CRP & CAC Scoringhs-CRP & CAC Scoring In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals CAC Scanning with CTCAC Scanning with CT && hs-CRP testinghs-CRP testing areare ComplementaryComplementary to each otherto each other and the combination of bothand the combination of both can be used to refinecan be used to refine Clinical-Decision making in such patientsClinical-Decision making in such patients